135 related articles for article (PubMed ID: 9223544)
1. Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.
De Luca A; Pierno S; Natuzzi F; Franchini C; Duranti A; Lentini G; Tortorella V; Jockusch H; Camerino DC
J Pharmacol Exp Ther; 1997 Jul; 282(1):93-100. PubMed ID: 9223544
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide.
De Luca A; Natuzzi F; Falcone G; Duranti A; Lentini G; Franchini C; Tortorella V; Camerino DC
Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):777-87. PubMed ID: 9453464
[TBL] [Abstract][Full Text] [Related]
3. Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels.
Duranti A; Franchini C; Lentini G; Loiodice F; Tortorella V; De Luca A; Pierno S; Conte Camerino D
Eur J Med Chem; 2000 Jan; 35(1):147-56. PubMed ID: 10733611
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective effects of mexiletine enantiomers on sodium currents and excitability characteristics of adult skeletal muscle fibers.
De Luca A; Natuzzi F; Lentini G; Franchini C; Tortorella V; Conte Camerino D
Naunyn Schmiedebergs Arch Pharmacol; 1995 Dec; 352(6):653-61. PubMed ID: 9053738
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.
De Luca A; Talon S; De Bellis M; Desaphy JF; Franchini C; Lentini G; Catalano A; Corbo F; Tortorella V; Conte-Camerino D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):318-27. PubMed ID: 12644906
[TBL] [Abstract][Full Text] [Related]
6. Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.
Desaphy JF; Conte Camerino D; Franchini C; Lentini G; Tortorella V; De Luca A
Br J Pharmacol; 1999 Nov; 128(6):1165-74. PubMed ID: 10578128
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.
Carocci A; Catalano A; Bruno C; Lentini G; Franchini C; De Bellis M; De Luca A; Conte Camerino D
Chirality; 2010 Mar; 22(3):299-307. PubMed ID: 19544349
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels.
De Luca A; Natuzzi F; Desaphy JF; Loni G; Lentini G; Franchini C; Tortorella V; Camerino DC
Mol Pharmacol; 2000 Feb; 57(2):268-77. PubMed ID: 10648636
[TBL] [Abstract][Full Text] [Related]
9. New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.
De Luca A; Pierno S; Liantonio A; Desaphy JF; Natuzzi F; Didonna MP; Ferrannini E; Jockusch H; Franchini C; Lentini G; Corbo F; Tortorella V; Camerino DC
Neuromuscul Disord; 2004 Jul; 14(7):405-16. PubMed ID: 15210163
[TBL] [Abstract][Full Text] [Related]
10. Antimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goats.
Camerino DC; Pierno S; De Luca A; Bryant SH
Neuromuscul Disord; 2000 Mar; 10(3):160-4. PubMed ID: 10734261
[TBL] [Abstract][Full Text] [Related]
11. Dual Action of Mexiletine and Its Pyrroline Derivatives as Skeletal Muscle Sodium Channel Blockers and Anti-oxidant Compounds: Toward Novel Therapeutic Potential.
De Bellis M; Sanarica F; Carocci A; Lentini G; Pierno S; Rolland JF; Conte Camerino D; De Luca A
Front Pharmacol; 2017; 8():907. PubMed ID: 29379434
[TBL] [Abstract][Full Text] [Related]
12. Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia.
Desaphy JF; Camerino DC; Tortorella V; De Luca A
Neuromuscul Disord; 1999 May; 9(3):182-9. PubMed ID: 10382914
[TBL] [Abstract][Full Text] [Related]
13. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.
De Bellis M; Carbonara R; Roussel J; Farinato A; Massari A; Pierno S; Muraglia M; Corbo F; Franchini C; Carratù MR; De Luca A; Conte Camerino D; Desaphy JF
Neuropharmacology; 2017 Feb; 113(Pt A):206-216. PubMed ID: 27743929
[TBL] [Abstract][Full Text] [Related]
14. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative.
Desaphy JF; De Luca A; Tortorella P; De Vito D; George AL; Conte Camerino D
Neurology; 2001 Nov; 57(10):1849-57. PubMed ID: 11723275
[TBL] [Abstract][Full Text] [Related]
15. Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.
Franchini C; Carocci A; Catalano A; Cavalluzzi MM; Corbo F; Lentini G; Scilimati A; Tortorella P; Camerino DC; De Luca A
J Med Chem; 2003 Nov; 46(24):5238-48. PubMed ID: 14613326
[TBL] [Abstract][Full Text] [Related]
16. Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo.
Desaphy JF; Farinato A; Altamura C; De Bellis M; Imbrici P; Tarantino N; Caccia C; Melloni E; Padoani G; Vailati S; Keywood C; Carratù MR; De Luca A; Conte D; Pierno S
Exp Neurol; 2020 Jun; 328():113287. PubMed ID: 32205118
[TBL] [Abstract][Full Text] [Related]
17. Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.
Talon S; De Luca A; De Bellis M; Desaphy JF; Lentini G; Scilimati A; Corbo F; Franchini C; Tortorella P; Jockusch H; Conte Camerino D
Br J Pharmacol; 2001 Dec; 134(7):1523-31. PubMed ID: 11724759
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.
De Bellis M; De Luca A; Rana F; Cavalluzzi MM; Catalano A; Lentini G; Franchini C; Tortorella V; Conte Camerino D
Br J Pharmacol; 2006 Oct; 149(3):300-10. PubMed ID: 16921388
[TBL] [Abstract][Full Text] [Related]
19. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
Wang GK; Russell C; Wang SY
J Physiol; 2004 Feb; 554(Pt 3):621-33. PubMed ID: 14608007
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Desaphy JF; Carbonara R; Costanza T; Conte Camerino D
Exp Neurol; 2014 May; 255(100):96-102. PubMed ID: 24613829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
